Speaking on the above topic is Mr Klaus Kaiser, Head GMP Purification Global / Global Biological Development, Bayer Healthcare LLC, United States. He will be presenting at Biologic Manufacturing World Asia 2012, part of a series of conferences in the 5th Annual BioPharma Asia Convention 2012, held on 19-22 March at Marina Bay Sands, Singapore.
Mr Kaiser received his Ph.D. in Biochemistry at the Laboratory for Molecular Biology / Gene Center of Ludwig-Maximilians-University Munich. He joined Bayer in 1997 and worked as Project Manager in Bioprocess Engineering for Bayer Technology Services in Leverkusen followed by a short-term consulting assignment at Bayer Corporation in Berkeley, Ca. With several years of CMC experience Mr Kaiser is currently holding a position as Senior Scientist and heading a manufacturing facility at Bayer Pharma, Biotech Development. He is responsible for development of downstream processes and for the production of antibodies and antibody fragments for clinical investigations.
Mr Kaiser will be speaking on the below topics:
A practical approach to Design of Experiments for downstream processing of antibody fragments
1. Innovating platform processes for antibody fragments through increased flexibility in downstream process development
2. Applying QbD in the lean development concept to enhance downstream processing development
3. Developing a general approach based on several case studies on Design of Experiments in early and late stage development of downstream processes for antibody fragments